» Articles » PMID: 35340294

An Blood-brain Barrier Model to Study the Penetration of Nanoparticles

Overview
Journal Bio Protoc
Specialty Biology
Date 2022 Mar 28
PMID 35340294
Authors
Affiliations
Soon will be listed here.
Abstract

The blood-brain barrier (BBB), a crucial protection mechanism in the central nervous system (CNS), is a selective barrier comprised of endothelial cells. It hampers the development of therapeutic and diagnostic tools for neurological diseases due to the poor penetration of most of these agents. Rationally engineered nanoparticles (NP) can facilitate the transport of therapeutic and diagnostic agents across the BBB. However, evaluating BBB penetration by NP majorly relies on the use of expensive and time-consuming animal experiments with low throughput. BBB models composed of brain endothelial cells can be a useful tool to rapidly screen multiple NP formulations to compare their BBB penetration ability and identify optimal formulations for validation. In this protocol, we present an model of BBB developed using murine cerebral cortex endothelial cells (bEnd.3). bEnd.3 is a commercially available, easy to manipulate cell line that forms tight junctions with potent paracellular barrier property. The protocol includes culturing of bEnd.3 cells, establishment of the model, and assessing NP permeability. We believe that, due to its simplicity and consistency, this step-by-step protocol can be easily used by researchers to screen NP-based drug delivery systems for BBB penetration. Graphic abstract.

Citing Articles

Synthesis and Characterization of Memantine-Loaded Niosomes for Enhanced Alzheimer's Disease Targeting.

Turkez H, Oner S, Yildirim O, Arslan M, Dimmito M, Kahraman C Pharmaceutics. 2025; 17(2).

PMID: 40006634 PMC: 11860023. DOI: 10.3390/pharmaceutics17020267.


Adipose-Derived Stem Cells as Carrier of Pro-Apoptotic Oncolytic Myxoma Virus: To Cross the Blood-Brain Barrier and Treat Murine Glioma.

Jazowiecka-Rakus J, Pogoda-Mieszczak K, Rahman M, McFadden G, Sochanik A Int J Mol Sci. 2024; 25(20).

PMID: 39457007 PMC: 11508294. DOI: 10.3390/ijms252011225.


Engineered Selenium/Human Serum Albumin Nanoparticles for Efficient Targeted Treatment of Parkinson's Disease via Oral Gavage.

Xu K, Huang P, Wu Y, Liu T, Shao N, Zhao L ACS Nano. 2023; 17(20):19961-19980.

PMID: 37807265 PMC: 10604087. DOI: 10.1021/acsnano.3c05011.

References
1.
Pardridge W . Blood-brain barrier drug targeting: the future of brain drug development. Mol Interv. 2004; 3(2):90-105, 51. DOI: 10.1124/mi.3.2.90. View

2.
Aday S, Cecchelli R, Hallier-Vanuxeem D, Dehouck M, Ferreira L . Stem Cell-Based Human Blood-Brain Barrier Models for Drug Discovery and Delivery. Trends Biotechnol. 2016; 34(5):382-393. DOI: 10.1016/j.tibtech.2016.01.001. View

3.
van Rooy I, Cakir-Tascioglu S, Hennink W, Storm G, Schiffelers R, Mastrobattista E . In vivo methods to study uptake of nanoparticles into the brain. Pharm Res. 2010; 28(3):456-71. PMC: 3044085. DOI: 10.1007/s11095-010-0291-7. View

4.
Pardridge W . The blood-brain barrier: bottleneck in brain drug development. NeuroRx. 2005; 2(1):3-14. PMC: 539316. DOI: 10.1602/neurorx.2.1.3. View

5.
Bozdag Pehlivan S . Nanotechnology-based drug delivery systems for targeting, imaging and diagnosis of neurodegenerative diseases. Pharm Res. 2013; 30(10):2499-511. DOI: 10.1007/s11095-013-1156-7. View